openPR Logo
Press release

Global Neuroendocrine Tumor Treatment Market

06-29-2017 05:21 PM CET | Health & Medicine

Press release from: Clinical Diagnostic Report By CMI

The Global Neuroendocrine Tumor Treatment Market was valued at US$ 1,197.3 million in 2016 and is projected to expand at a CAGR of 10.5% during the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Better diagnostic techniques and products in pipeline are expected to be major factors driving growth of the global neuroendocrine tumor treatment market over the foreseeable future.

Neuroendocrine Tumor (NET) are diagnosed more frequently in the U.S. than other countries worldwide. According to U.S. Surveillance Epidemiology and End Results (SEER) Register, in 35 years prior to 2016, the number of GI neuroendocrine tumors/carcinomas of the small intestine has increased 300%-500%, which will drive an ample opportunity for the emerging pharma companies focusing on neuroendocrine tumor treatment drugs. Pulmonary neuroendocrine tumor treatment comprise around 25% of all kinds of neuroendocrine tumor treatment. According to Louisiana State University Health Sciences Center, 2016, Pulmonary Neuroendocrine Tumor Treatment have a low incidence in the U.S., with a rate of 1.6/100,000 individuals. Typical Carcinoid (TC) comprise 1-2% and Atypical Carcinoid (AC) comprise 0.1-0.2% of all pulmonary tumors, whereas small cell lung carcinoma (SCLC) and Large Cell Neuroendocrine Carcinoma (LCNECs) make up 20% and 1.6-3%, respectively

Overall survival is good for the well-differentiated Typical Carcinoid tumors is 92-100% and moderate for AC 61-88%, whereas the higher grade, poorly differentiated SCLC and LCNET have a grim prognosis with OS as low as 5%

Request a sample copy of this report@
https://www.coherentmarketinsights.com/insight/request-sample/129

According to stats released by the American Society of Clinical Oncology in 2014, an estimated 12,000 people are diagnosed with a neuroendocrine tumor and 1,500 people are diagnosed with Merkel cell skin cancer in the U.S. each year. Most of the patients were in the age group 60-65 years, with 90% are white people. This disease if undiagnosed within the first two years of its occurrence, reduces survival rate to around 60%. Survival rate of neuroendocrine cancer becomes much higher if it is detected in early stages, prior spreading to the lymph nodes or any distant parts of the human body. The GI neuroendocrine tumor is the one of the most common indication causing liver metastases, particularly when it effected in the midgut origin. Appendix is the second most common location for midgut carcinoids it acts as a carrier for the spread of the disease to entire liver.

Around 90 out of 100 people survive for 5 years or more if the carcinoid started in the appendix gastrointestinal neuroendocrine tumors is inherently a diverse group of cells or tumors that sometimes generate various peptides triggering characteristic hormonal disorders. Neuroendocrine tumor treatment can be categorized into clinically symptomatic (functioning) or silent (non-functioning). Both types of NET produce more than one peptide, though these are not associated with specific syndromes.

Browse report summery with TOC:
https://www.coherentmarketinsights.com/market-insight/neuroendocrine-tumors-treatment-market-129#3a

Key take aways of the neuroendocrine tumor treatment market:

The global neuroendocrine tumor treatment market is expected to expand at a CAGR of 10.5% during the forecast period (2017–2025) as there exists a huge unrealized market especially in Asia Pacific, Latin America, Middle East and Africa
The Sunitinib Malate and Sufatinib dominates the market in the drug segment, as it is used to treat progressive, well-differentiated advanced and/or metastatic pancreatic neuroendocrine tumors and show a good tolerance in Grade 3 NET patients too.
Gastrointestinal neuroendocrine tumor and pancreatic neuroendocrine tumor are the major indication segment of neuroendocrine tumor treatment market, as these indication are highly prevalent in regions like North America and Asia Pacific
Some of the major players involved in global neuroendocrine tumor treatment market are Pfizer Inc, Novartis AG, Ispen, Advanced Accelerator Applications, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc.and Exelixis, Inc.

Get More Details about this Report@
https://www.coherentmarketinsights.com/market-insight/neuroendocrine-tumors-treatment-market-129

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Neuroendocrine Tumor Treatment Market here

News-ID: 601895 • Views: 256

More Releases from Clinical Diagnostic Report By CMI

Sepsis Diagnostic Market-Global Industry Insights, Trends, Outlook
Sepsis is life threatening complication caused due to the infection, which can result into organ failure, tissue damage, and ultimately lead to death if left untreated. If sepsis progresses to septic shock, it cause sudden drop in blood pressure and may leads to death of patient. Sepsis occurs due the infection in any part of the body. However the most common site of infections leading to the sepsis are lungs,
Liquid Biopsy Market - Insights
Liquid biopsy involves testing of the blood to identify biomarkers or cancer cells in the form of cells or pieces of DNA which are separated from the tumor and are circulating in the blood. Liquid biopsy helps in early detection of cancer, which would aid in adopting an optimal treatment plan. It is a non-invasive technique, which makes frequent testing possible, and effectiveness of cancer treatment can also be validated
Enteric Disease Testing Market - Global Industry Insights 2025
Enteric infection is a type of intestinal disease that causes symptoms ranging from mild gastroenteritis to systemic infections and severe diarrhea. According to WHO in 2017, Infectious gastroenteritis accounts for 1 billion cases of diarrhea globally and over 2 million deaths annually. In addition to this, according to Bill and Melinda Gates Foundation, 2017, enteric and diarrheal diseases leads to death of about 500,000 children, under the age of five
Hospital Acquired Disease Testing Market to Surpass US$ 2.7 Billion by 2025 Glob …
Hospital acquired Disease Testing – Hospital or Mortuary Hospital acquired disease or nosocomial infection is a localized or systemic condition in patients occurred due to adverse reaction caused by infectious toxin agents under medical care and were absent at the time of admission. Hospitals acquired infections results in prolonged hospital stay, antimicrobial resistance, long-term disabilities, and increase mortality rate. Pathogens responsible for nosocomial infections include viruses, fungal parasites, and bacteria. Hospital acquired

All 5 Releases


More Releases for Neuroendocrine

Neuroendocrine Tumours Therapeutics Market | Global Industry Report 2019 - 2025
Neuroendocrine Tumours Therapeutics Market: Market Share, Size, Targeted Market And More Neuroendocrine tumours (NET) are the abnormal growths which begin in neuroendocrine cells. Neuroendocrine which are similar to the nerve cells and hormones producing cells. Neuroendocrine tumours are rare and can occur anywhere in the body such as small intestine, lungs, rectum, appendix, and pancreas. Neuroendocrine tumours can be noncancerous (benign) or cancerous (malignant). NETs will arises from several neuroendocrine cells
Neuroendocrine Carcinoma Market Analysis & Key Trends 2020
A neuroendocrine tumor is a kind of tumor that begins in the hormone producing cells of the neuroendocrine system that is made up of the endocrine system and nervous system. Hormones producing neuroendocrine cells have a structure similar to neurons and produce hormones like endocrine cells. These cells are found throughout the body in organs such as intestines, kidneys, lungs and stomach and perform functions such as controlling the speed
Neuroendocrine Tumors Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2017, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape. Neuroendocrine tumor begins in the hormone-producing cells of the body's neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part
Neuroendocrine Tumors Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2017, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape. Neuroendocrine tumor begins in the hormone-producing cells of the body's neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part
Neuroendocrine Carcinoma Market Analysis and Supply Demand 2016-2026
Neuroendocrine tumors (NETs) are malignant tumors that originate in endocrine cells and targets digestive tract that misbalances hormonal release. Neuroendocrine tumors are three types which include Pheochromocytoma, Merkel cell cancer, and neuroendocrine carcinoma. Neuroendocrine cells also present in the neuroendocrine system that includes pituitary gland, pineal gland, thyroid gland, parathyroid and adrenal glands. Physiological changes in the neuroendocrine cells may cause formation of two types of tumors–functional and nonfunctional tumors.
New Research: Global Neuroendocrine Tumors Market
MarketResearchReports.Biz presents this most up-to-date research on "Neuroendocrine Tumors-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" Report, Neuroendocrine Tumors-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Neuroendocrine Tumors Report is to understand the market and pipeline status of the drugs around the Neuroendocrine